BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. 2001

E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.

BACKGROUND Nelfinavir dosed at approximately 20 to 30 mg/kg three times a day (TID) in older children provides exposure similar to 750 mg TID in adults. However, the pharmacokinetics (PK) of nelfinavir in infants who are < 2 years of age is not well-described. The objective of this study was to determine the pharmacokinetics of nelfinavir in infants < 2 years of age. METHODS Nelfinavir concentrations were evaluated in 22 HIV-infected infants between 15 days and 2 years of age receiving nelfinavir as part of Pediatric ACTG Study 356. Nelfinavir therapy was initiated at approximately 25 mg/kg TID (n = 18) or approximately 55 mg/kg twice a day (n = 4) and given in combination with nevirapine, stavudine and lamivudine. PK samples were obtained predose and 1.5 and 4 h postdose at approximately 6-month intervals. Eight infants (all < or = 3 months of age) also had intensive PK samples collected at Week 1. RESULTS The median apparent clearance in the infants with intensive pharmacokinetic sampling was 2.7 liters/h/kg (range, 1.8 to > or = 10) and was similar between twice a day and TID dosing cohorts. Overall nelfinavir concentrations at all collection times were lower in these infants than previously reported in older pediatric patients. CONCLUSIONS Nelfinavir concentrations in infants are highly variable and lower than those seen in adult or older pediatric populations receiving labeled dosing. Therefore it is necessary to further evaluate nelfinavir safety, effectiveness and pharmacokinetics at higher doses than used among other pediatric populations.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
March 2004, Antimicrobial agents and chemotherapy,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
January 2003, The Pediatric infectious disease journal,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.
December 2007, Antimicrobial agents and chemotherapy,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
May 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
December 2002, Antimicrobial agents and chemotherapy,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
June 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
December 2001, Antimicrobial agents and chemotherapy,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Pharmacokinetics of dapsone in human immunodeficiency virus-infected children.
May 1995, Antimicrobial agents and chemotherapy,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.
August 2000, British journal of clinical pharmacology,
E V Capparelli, and J L Sullivan, and L Mofenson, and E Smith, and B Graham, and P Britto, and M I Becker, and D Holland, and J D Connor, and K Luzuriaga, and
Hypogammaglobulinemia in infants infected with human immunodeficiency virus.
April 1989, Southern medical journal,
Copied contents to your clipboard!